WALTHAM, Mass. – (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics, announced today the appointment of Stephen R. Miller to the newly created position of Chief Commercial Officer. Steve has over 20 years of experience in the diagnostics industry, serving recently as Vice President of Sales and Marketing at Athena Diagnostics Inc., where he was instrumental in driving Athena’s core business growth and expansion into new markets.

“Steve’s wealth of experience in introducing and commercializing innovative diagnostic tests provides us with strong commercial leadership for our BGM Galectin 3™ test for heart failure and the planned introduction of the automated galectin-3 tests in 2012,”

said Pieter Muntendam, President and CEO of BG Medicine. 

“We are proud to add this high caliber executive to our management team at this important time in our company’s growth and development.” 

“The combination of potentially transformative diagnostics for large markets and a business model that leverages partnerships with the leading diagnostics companies has created a very exciting opportunity for BG Medicine,”

 said Steve Miller. 

“I am looking forward to using my commercial experience and industry relationships to deliver on the promises of BG Medicine’s innovative products.”

Prior to joining BG Medicine, Steve held the positions of Chief Commercial Officer and President of MiraDx. Previously, Steve served in positions of increasing responsibility at Athena Diagnostics, most recently as Vice President of Sales and Marketing, where he was instrumental in the launch of more than 200 products into the healthcare market. His positions during his tenure there included Director of Corporate Accounts, where he led the strategic development of national accounts, clinical trials, managed care and training programs; and Regional Sales Manager. Prior to Athena Diagnostics, Steve served in various sales and training positions at Athena Neurosciences, Inc., an indirect wholly-owned subsidiary of Elan prior to its acquisition by Elan in 1996, and as a member of its initial neurology pharmaceutical sales force. He began his career as a pharmaceutical sales representative at Wyeth-Ayerst laboratories. Steve holds a B.A. from Miami University in Oxford, Ohio. 

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs. With an initial focus on products to advance cardiovascular care, BG Medicine recently launched the BGM Galectin-3TM test for heart failure, the first novel blood test for cardiac disease cleared by the U.S. F.D.A. in five years. For additional information about BG Medicine and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=8765

CONTACT: Stacie Rader
Corporate Communications
+1 (781) 890-1199 

Source: BG Medicine Inc.